Compare YRD & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | YRD | NGNE |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.8M | 327.8M |
| IPO Year | 2015 | N/A |
| Metric | YRD | NGNE |
|---|---|---|
| Price | $4.51 | $20.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $38.50 |
| AVG Volume (30 Days) | 75.8K | ★ 239.9K |
| Earning Date | 11-25-2025 | 11-13-2025 |
| Dividend Yield | ★ 9.76% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.03 | N/A |
| Revenue | ★ $872,820,262.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.23 | ★ N/A |
| Revenue Growth | ★ 10.41 | N/A |
| 52 Week Low | $4.15 | $6.88 |
| 52 Week High | $8.74 | $37.27 |
| Indicator | YRD | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 36.66 | 39.47 |
| Support Level | $4.27 | $19.23 |
| Resistance Level | $4.64 | $23.00 |
| Average True Range (ATR) | 0.21 | 1.60 |
| MACD | 0.02 | -0.09 |
| Stochastic Oscillator | 37.14 | 26.57 |
Yiren Digital Ltd is an AI-powered platform providing a comprehensive suite of financial and lifestyle services in China. Its mission is to elevate customers' financial well-being and enhance their quality of life by delivering digital financial services, tailor-made insurance solutions, and premium lifestyle services. The company supports clients at various growth stages, addressing financing needs arising from consumption and production activities, while aiming to augment the overall well-being and security of individuals, families, and businesses.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.